DDInter537 DDInter364
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Diclofenac {u} (Compound) causes {v} (Side Effect) Water retention
Water retention {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Probenecid and Probenecid (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Diclofenac (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Chlorpropamide (Compound)
Diclofenac (Compound) causes Water retention (Side Effect) and Water retention (Side Effect) is caused by Chlorpropamide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Probenecid and Probenecid (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)